



**KINEXUS**

## **Kinexus Announces Two New Phosphoprotein Screening Services**

*Kinetworks™ Phosphoprotein Arrays Developed in Collaboration with Biosource International*

**FOR IMMEDIATE RELEASE JULY 23, 2003**

**VANCOUVER, British Columbia** – Kinexus Bioinformatics Corporation, a Canadian proteomics company, is pleased to announce the release of two new Kinetworks™ Phosphoprotein Screening Services, KPSS 2.0 and 3.0, for simultaneously tracking the presence and activation states of over 60 different regulatory and cell signaling proteins. These screens were developed in collaboration with Biosource International, a life sciences company that develops and markets biologically active reagents for pharmaceutical and biomedical research.

The Kinetworks™ approach for the detection of phosphoproteins is unique in the marketplace and unrivalled for its reliability and sensitivity. Utilizing a proprietary technology, the services are designed to assist biomedical researchers in academia and the biopharmaceutical industry in the discovery of new drug targets, new drugs and the molecular diagnosis of disease. The first phosphoprotein screen has uncovered promising research leads in important disease states, such as a 150-fold increase in the phosphorylation level of adducin found in the spinal cord of ALS patients compared to patient matched controls. [Hu et al. (2003) J. Neurochem]. All publications referencing the Kinetworks™ technology can be viewed at [www.kinexus.ca](http://www.kinexus.ca).

“We are very excited by the power of our Kinetworks™ technology to successfully identify novel targets for drug discovery for treatment of cancer and other diseases,” said Dr. Steven Pelech, President and Founder of Kinexus and a Professor at the University of British Columbia. Kinexus represents his vision of creating a company that provides crucial sophisticated information about potential drug targets, while at the same time advancing the signal transduction field in a quantum way over other approaches. Kinexus currently offers 9 signal transduction protein profiling services for the detection of over 300 known cell signaling proteins, with revolutionary new platform technologies under development.

Kinexus Bioinformatics Corporation is a private, biopharmaceutical company engaged in the research and development of innovative methods to understand the relationships of signaling proteins in cellular communication networks. The application of this knowledge positions Kinexus and its clients in drug development, rational drug design, disease diagnosis and personalized therapies to improve human health.

**For further information, please contact Kinexus Bioinformatics Corporation  
toll free at 1-866-KINEXUS or visit our website at [www.kinexus.ca](http://www.kinexus.ca)**

**PRESS RELEASE - 2003 JULY 23**